{"pmid":32340979,"title":"Online management of rheumatoid arthritis during COVID-19 pandemic.","text":["Online management of rheumatoid arthritis during COVID-19 pandemic.","Ann Rheum Dis","Zhang, Yang","Wang, Jian","Zhao, Liang","Xiao, Jun","Shi, Zhanjun","32340979"],"journal":"Ann Rheum Dis","authors":["Zhang, Yang","Wang, Jian","Zhao, Liang","Xiao, Jun","Shi, Zhanjun"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32340979","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1136/annrheumdis-2020-217548","keywords":["arthritis","arthritis, rheumatoid","health services research"],"topics":["Prevention"],"weight":1,"_version_":1665351883924963330,"score":8.574329,"similar":[{"pmid":32205186,"pmcid":"PMC7102591","title":"COVID-19 infection and rheumatoid arthritis: Faraway, so close!","text":["COVID-19 infection and rheumatoid arthritis: Faraway, so close!","The outbreak of the new coronavirus infections COVID-19 in December 2019 in China has quickly become a global health emergency. Given the lack of specific anti-viral therapies, the current management of severe acute respiratory syndrome coronaviruses (SARS-CoV-2) is mainly supportive, even though several compounds are now under investigation for the treatment of this life-threatening disease. COVID-19 pandemic is certainly conditioning the treatment strategy of a complex disorder as rheumatoid arthritis (RA), whose infectious risk is increased compared to the general population because of an overall impairment of immune system typical of autoimmune diseases combined with the iatrogenic effect generated by corticosteroids and immunosuppressive drugs. However, the increasing knowledge about the pathophysiology of SARS-CoV-2 infection is leading to consider some anti-rheumatic drugs as potential treatment options for the management of COVID-19. In this review we will critically analyse the evidences on either positive or negative effect of drugs commonly used to treat RA in this particular scenario, in order to optimize the current approach to RA patients.","Autoimmun Rev","Favalli, Ennio Giulio","Ingegnoli, Francesca","De Lucia, Orazio","Cincinelli, Gilberto","Cimaz, Rolando","Caporali, Roberto","32205186"],"abstract":["The outbreak of the new coronavirus infections COVID-19 in December 2019 in China has quickly become a global health emergency. Given the lack of specific anti-viral therapies, the current management of severe acute respiratory syndrome coronaviruses (SARS-CoV-2) is mainly supportive, even though several compounds are now under investigation for the treatment of this life-threatening disease. COVID-19 pandemic is certainly conditioning the treatment strategy of a complex disorder as rheumatoid arthritis (RA), whose infectious risk is increased compared to the general population because of an overall impairment of immune system typical of autoimmune diseases combined with the iatrogenic effect generated by corticosteroids and immunosuppressive drugs. However, the increasing knowledge about the pathophysiology of SARS-CoV-2 infection is leading to consider some anti-rheumatic drugs as potential treatment options for the management of COVID-19. In this review we will critically analyse the evidences on either positive or negative effect of drugs commonly used to treat RA in this particular scenario, in order to optimize the current approach to RA patients."],"journal":"Autoimmun Rev","authors":["Favalli, Ennio Giulio","Ingegnoli, Francesca","De Lucia, Orazio","Cincinelli, Gilberto","Cimaz, Rolando","Caporali, Roberto"],"date":"2020-03-25T11:00:00Z","year":2020,"_id":"32205186","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.autrev.2020.102523","keywords":["COVID-19","Coronavirus","Cytokine release syndrome","DMARDs","Rheumatoid arthritis","Treatment"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1663352133689278465,"score":105.28202},{"pmid":32241793,"title":"Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies.","text":["Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies.","Ann Rheum Dis","Monti, Sara","Balduzzi, Silvia","Delvino, Paolo","Bellis, Elisa","Quadrelli, Verdiana Serena","Montecucco, Carlomaurizio","32241793"],"journal":"Ann Rheum Dis","authors":["Monti, Sara","Balduzzi, Silvia","Delvino, Paolo","Bellis, Elisa","Quadrelli, Verdiana Serena","Montecucco, Carlomaurizio"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32241793","week":"202014|Mar 30 - Apr 05","doi":"10.1136/annrheumdis-2020-217424","keywords":["antirheumatic agents","arthritis, rheumatoid","biological therapy","spondylitis, ankylosing"],"link_comment_in":"32299844","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664638249418620929,"score":97.1389},{"pmid":32321722,"title":"To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (COVID-19) pandemic.","text":["To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (COVID-19) pandemic.","Ann Rheum Dis","Parperis, Konstantinos","32321722"],"journal":"Ann Rheum Dis","authors":["Parperis, Konstantinos"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32321722","week":"202017|Apr 20 - Apr 26","doi":"10.1136/annrheumdis-2020-217557","keywords":["arthritis","hydroxychloroquine","lupus erythematosus","rheumatoid","systemic"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664895932632662017,"score":71.52427},{"pmid":32314010,"title":"Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs.","text":["Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs.","In December 2019, numerous coronavirus disease 2019 (COVID-19) cases were reported in Wuhan, China, which has since spread throughout the world. However, its impact on rheumatoid arthritis (RA) patients is unknown. Herein, we report a case of COVID-19 pneumonia in a 61-year-old female RA patient who was receiving conventional disease-modifying antirheumatic drugs (cDMARDs). The patient presented with a 4-day history of myalgia and febrile sensation. COVID-19 was confirmed by real-time polymerase chain reaction (PCR). Chest X-ray showed increased opacity on the right lower lung area, and C-reactive protein level was slightly elevated. The patient was treated with antiviral agents (lopinavir/ritonavir), and treatment with cDMARDs was discontinued except hydroxychloroquine. Her symptoms and laboratory results gradually improved. Three weeks later, real-time PCR for COVID-19 showed negative conversion, and the patient was discharged without any complications.","Rheumatol Int","Song, Jehun","Kang, Seongmin","Choi, Seung Won","Seo, Kwang Won","Lee, Sunggun","So, Min Wook","Lim, Doo-Ho","32314010"],"abstract":["In December 2019, numerous coronavirus disease 2019 (COVID-19) cases were reported in Wuhan, China, which has since spread throughout the world. However, its impact on rheumatoid arthritis (RA) patients is unknown. Herein, we report a case of COVID-19 pneumonia in a 61-year-old female RA patient who was receiving conventional disease-modifying antirheumatic drugs (cDMARDs). The patient presented with a 4-day history of myalgia and febrile sensation. COVID-19 was confirmed by real-time polymerase chain reaction (PCR). Chest X-ray showed increased opacity on the right lower lung area, and C-reactive protein level was slightly elevated. The patient was treated with antiviral agents (lopinavir/ritonavir), and treatment with cDMARDs was discontinued except hydroxychloroquine. Her symptoms and laboratory results gradually improved. Three weeks later, real-time PCR for COVID-19 showed negative conversion, and the patient was discharged without any complications."],"journal":"Rheumatol Int","authors":["Song, Jehun","Kang, Seongmin","Choi, Seung Won","Seo, Kwang Won","Lee, Sunggun","So, Min Wook","Lim, Doo-Ho"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314010","week":"202017|Apr 20 - Apr 26","doi":"10.1007/s00296-020-04584-7","keywords":["covid-19","coronavirus","disease-modifying antirheumatic drugs","pneumonia","rheumatoid arthritis"],"source":"PubMed","topics":["Case Report"],"weight":1,"locations":["Wuhan","China","myalgia"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["lopinavir-ritonavir drug combination","Hydroxychloroquine"],"_version_":1664714520041357312,"score":70.53821},{"pmid":32295788,"title":"Does hydroxychloroquine prevent the transmission of covid-19?","text":["Does hydroxychloroquine prevent the transmission of covid-19?","Ann Rheum Dis","Heldwein, Flavio L","Calado, Adriano","32295788"],"journal":"Ann Rheum Dis","authors":["Heldwein, Flavio L","Calado, Adriano"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32295788","week":"202016|Apr 13 - Apr 19","doi":"10.1136/annrheumdis-2020-217501","keywords":["health services research","lupus erythematosus, systemic","therapeutics"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Hydroxychloroquine"],"_version_":1664641388338216960,"score":67.30595}]}